Background/Aims: High blood pressure is a major risk factor for chronic kidney disease. Currently, single-target anti-hypertensive drugs are not designed for high blood pressurerelated organ damages. Danhong injection (DHI), made from the aqueous extracts of Radix Salviae miltiorrhizae and Flos Carthamus tinctorius, has various pharmacological effects, including BP lowering in SHR, mediated by the reduction of vascular remodeling and the up-regulation of Kallikrein-kinin system published recently by our team, yet if it renders renal protection remains unknown. The current study demonstrated a protective role of DHI in renal injury caused by hypertension and identified its molecular targets in the kidney of spontaneously hypertensive rats (SHR). Methods: Adult SHR and age/gender-matched normotensive Wistar-Kyoto (WKY) rats were treated with DHI, Losartan, or saline for 4 weeks. Serum levels of Creatinine (CRE), Micro-albumin (mAlb), Beta2-microglobulin (β2-MG), and Uric acid (UA) were detected using ELISA kits. Renal pathology was examined by hematoxylin and Eosin (H&E) stains. Microarray analysis was performed on kidney tissues, and gene expression changes were validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot analyses. Results: Renal histopathological scores showed that SHR exhibited serious kidney injury compared to normotensive WKY rats. The intervention with 
Introduction
Recently, chronic kidney disease (CKD) is on the increase due to global health burdens of hypertension. A large body of evidence shows that persistent rise in blood pressure level is a risk factor for CKD [1] . CKD attributable to high blood pressure (HBP) rose 27% to 101 million (95% confidence interval, 81-130 million) in 2013 [2] . Hypertension accelerates severe pathological renal injuries including diffuse vacuolar degeneration of renal tubular epithelial cells, loss of brush border, and so on [3, 4] .
Chronic hypertension induces renal dysfunction in most patients with progression to fibrosis and eventual chronic renal failure [5] . Regardless of the cause, once hypertension develops, a cycle of renal injury, nephrosclerosis, poor prognostic hypertension with progressive renal injury set in [6] . Renal damage in patients with hypertension could either be hypertensive nephrosclerosis caused by long-term essential hypertension characterized by focal ischemic glomerular/nephron loss occur over time without serious renal dysfunction in BP within the auto-regulatory range, or arteriolar nephrosclerosis (which affects all the vessels and occurring in patients with severe hypertension accompanied by acute disruptive vascular and glomerular injury with arteriolar necrosis and cast formation when the BP threshold within the auto-regulatory is exceeded) [6, 7] . Renal damage triggered by hypertension occurs as a consequence degree of exposure of blood vessel to an increased blood pressure [8, 9] .
Mb is a member of the hemoprotein superfamily, which includes hemoglobin, neuroglobin, and cytoglobin. In the event of a renal injury, myoglobin enters circulation along with other enzymes and electrolytes causing an excessive rise in the renal threshold that triggers myoglobinuria [10] . Since myoglobin maintains mean arterial pressure during a fall in volume using derived nitric oxide to increase the vascular resistance, it then worsens the renal ischemic injury. Hence, Mb is one of the early renal damage indicators with high sensitivity and specificity. It is also the most sensitive indicator in early diagnosis of acute tubular necrosis (ATN) [11] . In a clinical study of renal failure patient, the author showed a result with extreme levels of blood Mb higher than 10, 000 ng/mL and a predictability level of 0.88 based on area under the curve of acute renal failure with the best cutoff value of 3865 ng/mL for blood Mb [12] . On the other hand, urea nitrogen (UN) and serum creatinine (Scr) are indicators of renal impairment [13] . However, a study has shown low sensitivity to these indicators in an early renal damage [14] . Study also found a correlation of increased serum levels of Mb and early kidney damage caused by heart attack [15] , suggesting that serum Mb, Scr, blood UN index all have the advantages of accuracy and high sensitivity in the diagnosis of early renal function damage in SHR [16] . Quite a large amount of evidence suggests that pathophysiological mechanisms involved in Mb uric conditions are associated with renal dysfunction as well as important laboratory morphologic considerations [17, 18] based on high serum Mb or tissue Mb.
DHI, a widely prescribed injection medicine in China, is formulated based on the theory of traditional Chinese medicine (TCM), for blood activation and promotion of circulations to dissipate blood stasis and dredge collaterals. DHI is composed of extracts from Radix Salviae miltiorrhizae (Danshen) and Flos Carthami tinctorius (Honghua) [19] and has been used with proven efficacy and safety for treating various cardio-cerebrovascular diseases [20] . Although, DHI has many components, the main pharmacologically active components include phenolic acids, diterpenes, and flavonoids (salvianolic acid, danshensu, tanshinone, safflor yellow etc.) [21, 22] . We have previously characterized the major constituents of DHI by ultra-performance liquid chromatography (UPLC) [23] and proton nuclear magnetic resonance ( 1 H NMR) [24] . Recently, other investigators have separated and identified further constituents in DHI by UPLC [22] . Study has shown that DHI can significantly reduce plasma levels of endothelin-1, soluble P-selectin and high sensitive C-reactive protein in acute coronary syndrome patients, [25] and improves cardiac remodeling to preserve ventricular function in post-myocardial infarction rats [26] . In the previous study, we showed that DHI exerted an antihypertensive effect and vascular protection in SHR [27] . However, whether DHI has renal protective effect has not been explored.
The present study aimed to investigate (1) the potential of DHI in down-regulating Mb gene in CKD-challenged subject, (2) the ability to reduce serum level of KIM-1 in hypertension-mediated CKD, and (3) the renal protective effect/histological recovery and related mechanisms of DHI in SHR model by applying a combination of genomic and pharmacological approaches.
Materials and Methods
Danhong Injection DHI (Batch number: 12071086), a traditional Chinese Materia Medica standardized product extracted from Radix Salviae miltiorrhizae (Danshen) and Flos Carthami tinctorii (Honghua) with the raw material ratio of 3:1, was approved by China Food and Drug Administration (CFDA Permission Number Z20026866). DHI was formulated based on the pharmaceutical principle of blood activation to promote circulation and dissipate stasis. The high-performance liquid chromatography (HPLC) fingerprint analysis by authors shows consistency in the batches of DHI with statistical similarity value above 0.95 [19] . DHI was supplied by Heze Buchang Pharmaceutical CO., Ltd.
Reagents
Losartan was purchased from the Sichuan sea pureed pharmaceutical co., Ltd, (Yangtze River Pharmaceutical Group Dujiangyan, Sichuan, China). Saline was purchased from China Otsuka Pharmaceutical Co., Ltd (Tianjin, China). All other reagents were purchased from Sigma-Aldrich (St Louis, MO). Losartan was diluted in saline. Based on dose adjustment from the standard medical application, the original manufacture ampoule of DHI was administered to rats intraperitoneally (2.5 mL/kg/day) for 4 weeks.
Animals and Treatment
Adult (12-week-old) male SHR and age-matched male normotensive WKY rats, weighing about 200g, were purchased from Vital River Experimental Animal Technology Co., Ltd (Beijing, China). Rats were intraperitoneally injected with DHI (2.5 mL/Kg/day), Losartan (20 mg/Kg/day), and/or saline (2.5 mL/ Kg/day) for 4 weeks. Rats were maintained in a temperature-controlled room (25°C+/-1) under a cycle of 12 hours of light (beginning at 9:00 A.M.). All rats were given water and fed with standard chow. All animal care and operation procedures were strictly according to the China Laboratory Animal Use Regulations and were approved by the Institutional Animal Care and Use Committee at Tianjin International Joint Academy of Biotechnology and Medicine (TJAB-JY-2011-002), Tianjin, China.
After 4 weeks treatment, animals were anesthetized using an intraperitoneal injection of 10% Chloralic hydras. The blood serum was collected post-anesthesia and then stored at -20°C. Kidneys were harvested, one part was placed in 10% formalin for hematoxylin and eosin (H&E) staining, and the other part was snap-frozen in liquid nitrogen for microarray analysis, RT-PCR verification, and Western Blot analysis.
Blood Pressure Measurements
Noninvasive tail-cuff blood pressure (BP) measurements were performed on conscious rats every two days for 4 weeks after the initiation of the drug treatments using an 8-channel CODA noninvasive BP acquisition system (Kent Scientific Corporation, CT USA) as previously reported [27] . Systolic, diastolic, and mean BP as well as heart rate was recorded. For BP recording, eight separate measurements were obtained and averaged for each rat.
Invasive BP where measured using ADInstruments PowerLab 8/30 connected to bridge Amp ML 221 as previously reported [27] . Invasive BP was recorded after rats were treated with DHI and a change in BP was observed. Briefly, Animals were anesthetized with urethane followed by surgical manipulation. A heparinized saline, 100 IU/mL was placed in the transducer in clean polyethylene catheter cannulated to the ventricle through the left common carotid artery to prevent blood clotting. BP and HR were continuously recorded for 3 min each as waveform curve and the values where calculated.
Histological Studies
Renal specimens from each animal were fixed in 10% formalin, paraffin-embedded and sectioned at 5 μm thickness, deparaffinized and rehydrated. Histological staining was performed as previously described [28] ._ENREF_2 H&E were used for evaluating the general histology of kidney. The histological changes in the renal tissues were observed under a light microscope (Nikon Eclipse Ti). The renal histopathology scores were determined by two pathologists [19] based on the tubules expansion, cast formation, brush border loss, degeneration and necrosis of the epithelial cells. 5-point scoring system was used: 0 (normal, no damage); 1 point (10%); 2 points (11%-25%); 3 points (26%-45%); 4 points (46%-75%); and 5 points (76%-100%). At least 10 non-overlapping fields were randomly selected and observed per slice (original magnification X40 and enlarged sectional magnification of the original, X100).
Serum studies
After 4 weeks treatment with DHI, blood samples were collected, and diagnostic kits (ELISA Kit) were used to detect serum levels of mAlb and β 2 -MG (Genway Biotech, Inc San Diego California), Scr and UA (Abcam, Cambridge, UK) according to the manufacturers' instructions. For detailed procedures and all supplemental material see www.karger.com/doi/10.1159/000486735.
RNA Extraction
Total RNAs were extracted from the kidney using RNeasy Mini Kit (QIAGEN, Valencia, CA), following the manufacturer's protocol. RNA concentrations were measured by ultraviolet spectrophotometer including denaturing gel electrophoresis. All raw RNA samples were purified and then concentration adjusted to 50 ng/μL. The RNA samples were stored in liquid nitrogen before further processing for microarray analysis and qRT-PCR verification.
Microarray Analysis
Only the RNAs with RNA integrity numbers (RINs) greater than 7.0 and a 28S/18S ribosomal RNA (28SrRNA/18SrRNA) ratio more than 0.7 were used for microarray experiments. Gene expression data were generated using Affymetrix Rat-230 plus 2.0 arrays (Affymetrix, Inc. USA) for 3 independent animals. Each array consists of 31, 000 probe sets/genes (See details in Online Supplemental Materials pages 1 -3 and 5).
Quantitative Real-Time PCR qRT-PCR was performed to validate the microarray results. One microgram of total RNA from the same kidney was incubated with DNase I, and reverse-transcribed with oligo deoxythymine (DT) using superscript II qRT-PCR (TIANGEN). The RT product (200 ng) was amplified by primer pairs specific to the following genes: Mb, Dual oxidase 2 (Duox2) and Apolipoprotein B (ApoB). Beta-actin gene was used as a normalizing control. The primer sequences are listed in Supplementary Table S4 . SYBR Green PCR was performed using CFX96 Real-time system (Bio-Rad, CA, USA). For all reactions, a standard amplification program was used (2 min for a single cycle of 95°C, 30 sec at 44 cycles of 95°C, 40 sec at 60°C and 40 s at 72°C, 1 cycle of 95°C for 10 sec). The data was calculated by melting curve and 'Threshold Cycle' (Ct) using CFX Manager Software.
Protein Extraction
Total proteins were extracted from the rat's kidney using a BCA protein assay kit, following the manufacturer's protocol. Protein concentrations were measured by bicinchoninic acid assay (BCA) from Solarbio, and all raw protein samples were purified, and the concentration was adjusted to 5 ug/μL. The protein samples were stored at -80°C before Western Blot analysis.
Western Blot Analysis
Proteins were extracted from the kidneys of different groups of rats, and the concentration of protein was determined using a BCA protein assay kit. Aliquots of the organ lysates containing 50 µg of proteins were mixed with loading buffers, and then subjected to electrophoresis on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by routine Western blotting analysis, and the concentration of stacking gel and separation gel are 5% and 12%, respectively. The separated proteins were transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore) using wet transfer method at 260 mA for 1h. The membrane was blocked for 1 hour with TBST (150 mmol/L NaCl, 50 mmol/L Tris-HCl, pH 7.4, 0.1% Tween20) containing 5% bovine serum albumin (BSA) and then incubated overnight at 4 °C in primary antibody (anti-Mb at a 1:5000 dilution). Horseradish peroxidase (HRP) AffiniPure Goat Anti-Rabbit IgG (Beyotime) was added at a 1:5000 dilution for 1-2 hours followed by three washes in TBST for 15 minutes and β-actin (1:4000 dilution; Beyotime) was used as a loading control. Protein bands were visualized by enhanced chemiluminescence (Thermo) according to the standard protocols. The normal exposure times ranged from 10 s to 3 min. The developed films were scanned using Gel-pro analyzer for protein content estimation by the grayscale values. All values were normalized to total protein loaded onto the gels to allow for comparison between samples. The experiment was repeated four times, and the results obtained were presented as mean values of the sum of the four tests.
Statistical Analysis
All values are presented as means ± SEM with "n" being the number of individual rats. Statistical analyses were performed using the one-way ANOVA followed by Bonferroni multiple comparisons test (95% confidence interval) from SPSS 22. Origin 8.5.1 software (OriginLab Ltd, USA) was used for data analyses. Values of p < 0.05 were considered statistically significant.
Results

Effect of DHI against hypertension-induced renal injury in SHR
In one of our recent publication (Yang et al. 2017) [27] , Losartan (positive control drug) dramatically lowered diastolic, systolic, and mean BP in SHR starting from day 1 till after 4 weeks (*p < 0.05 vs SHR), we also found that treatment with DHI had no such immediate and aggressive effect on BP reduction in SHR as observed with Losartan, however diastolic, systolic, and mean BP were all significantly decreased compared to those of saline controls within 7 days till 4 weeks. The BP reduction effects of Danhong injection is associated in-path to the amelioration of vascular remodeling and up-regulation of the Kallikrein-kinin system.
Pathologically, H & E stain revealed histopathological changes in renal cortex among different groups as observed under a light microscope (Fig. 1A -D ). There were no obvious abnormalities in the tubular structure of renal tissues in WKY rats group (Fig. 1A) . Glomerulus from Saline-treated-SHR showed mesangial expansion, and focal glomerulosclerosis (Fig.  1B) compared to DHI/Losartan-treated-SHR (Fig. 1C -D) . Furthermore, compared to WKY rat group, the saline-treated SHR showed severe pathological renal injuries after 4 weeks (**p < 0.01), focal segmental glomerulosclerosis, shrunken glomerular tuft, with wrinkled capillary walls, a large scale of protein casts, wild spread erythrocyte accumulation, and tubular necrosis, (Fig. 1B) . DHI/Losartan-treated SHR showed a reduction in focal glomerulosclerosis, increased mesangial cellularity in the glomerulus, fewer lesions, better recovery, and lower pathological scores than untreated group starting from 4 weeks afterward (**p < 0.01 vs SHR, Fig. 1C -1E) .
DHI inhibits KIM-1 level in the kidney of SHR
Serum levels, including β 2 -MG, mAlb, UA, CRE, and KIM-1 were tested by ELISA kits. A significant difference was observed between DHI treatment and the control group based on the serum level of KIM-1 (*p < 0.05, Fig. 2E ). This finding agrees with the observed histological presentation.
We compare gene expression profiles between DHI-treatment and the control using Rat230 plus 2.0-microarray (31, 000 genes representation). Kidney from three independent animals per group were individually analyzed, and the results indicate that a total of 124 genes (90 up-regulation and 34 down-regulation) were altered when a cutoff t-test (*p < 0.05 and fold changes >1.2) were applied, (Fig. 3A and Supplementary Figure S2 ), see Supplementary Table S1 for detail list of differentially expressed genes by DHI treatment in the kidney of SHR and their fold change together with the statistical probability value. Consistent with the histopathological findings, among the genes altered, several were known to be associated with renal injury and protection, including Mb, Duox2, and ApoB (Fig. 3A -B,  Fig. 4, Supplementary Figure S1 and Supplementary Table S4 ). Their differential expressions were validated by qRT-PCR from the same RNA source. Interestingly, Mb gene expression in gene was significantly down-regulated in microarray by -2.74 -fold (details in Supplementary  Table S3) .
DHI decreased renal Mb expression in SHR
Western blot analysis was used to confirm whether DHI decreased renal Mb protein expression in hypertension-induced kidney injury. Compared with normal WKY rats, SHR expressed higher renal Mb protein. However, we found that DHI significantly decreased the protein expression (***p < 0.01 vs. SHR). Similarly, Losartan also reduced renal protein expression in SHR (Fig.  5A and B ). These data demonstrate that Mb protein overexpression is essential for kidney injury.
Interestingly, DHI exerted a renal protection to reverse Mb protein expressed.
Discussion
F o r m u l a t e d based on TCM theory of "activating and promoting blood circulations to dissipate blood stasis and dredge collaterals", DHI, a China food and drug administration approved injectable drug has been widely used in clinics with proven efficacy and safety [29] for treatment and prophylaxis of various cardiocerebrovascular diseases, such as ischemic-reperfusion injury, atherosclerosis, and acute coronary syndrome [20, 25, 30] . Previously, we found that DHI reversed vascular remodeling and exerted an antihypertensive effect through the Kallikrein-kinin system up-regulation in SHR [27] . In this present study, we now show that treatment with DHI/Losartan significantly reversed hypertension-induced kidney injury including renal injury biomarker KIM-1 and also provided renal-injury related genes suppression, particularly a down-regulation of renal myoglobin (Mb) gene expression confirmed by qRT-PCR and Western blot analysis.
SHR and WKY have the same number of nephrons, but the renal tubular system and glomerulus can be easily transformed pathologically during the renal insult. We specifically found severe pathological renal injuries in SHR (Fig. 1 B/b ) compared to their normotensive counterpart (Fig. 1A) . Interestingly, DHI/Losartan-treated SHR group prevented the development of the pathological abnormalities (Fig. 1C -1E) .
A large body of studies shows that DHI can effectively prevent the contrast-induced renal impairment and shorten the recovery time by restoring SCR, cystatin C (CysC), urine micro-albumin (mAlb), and β2-MG [31] . To investigate the renal protection of DHI, we first tested the markers of kidney injury (mAlb, β2-MG, CRE, UA, and KIM-1) on serum sample taken from SHR. Apart from KIM-1, DHI did not change most of these tested proteins compared to the control group ( Fig. 2A -E) . KIM-1 is a transmembrane tubular protein that is undetectable in normal kidneys but is markedly expressed in experimental renal injury including clinical studies, to be associated with renal fibrosis, inflammation, and tubular damage in chronic heart failure [32] . For example, in a mouse model of ischemic/reperfusion kidney injury, authors found that urinary KIM-1 and plasma KIM-1 levels were significantly elevated within 3 hours compared to their pre-operative levels [33] . In a study conducted in adult patients with kidney injury, diabetic or diabetic nephropathy, the author found an elevated level of KIM-1 in the diseased group but was significantly reduced after treatment [34] . Authors also found the KIM-1 as a urinary biomarker [35] and blood biomarker [33] in acute and chronic kidney injury. Interestingly, DHI significantly reduces the KIM-1 level in serum, which is accompanied by less renal histological damage in SHR (Fig. 1C and 2E) .
Because DHI is an herbal extract-derived medicine, its renal protection is possibly contributed by multiple components through a variety of mechanisms [36] . Therefore, we performed a microarray analysis of kidney genes to unfold the potential genes regulated by DHI and to investigate the mechanistic insights for its renal protection. Microarray data for the 6 samples were first analyzed by hierarchical clustering for quality evaluation and a comparison of the treatment effects. The biological replicates in each treatment group showed high reproducibility, judged by heat-map analysis (see Supplementary Figure S2A ). Our results indicate that DHI altered multiple pathways such as calcium signaling, apoptosis, natural killer cell mediated cytotoxicity signaling in the kidney of SHR (data not shown) [37] .
Among the 124 genes that were differentially regulated by DHI in SHR's kidney, Mb downregulation is of particular interest. Mb is known to play a key role in the development of acute renal damage due to its toxic accumulation in the renal tubular epithelium during the ultrafiltration process, [12] and it has been listed as a diagnostic marker and target for drug discovery for acute renal injury (ARI) [38] in conformity with the renal pathology which specifically showed severe pathologic renal injuries in the H&E stains.
Furthermore, we conducted integrated gene network analysis using ingenuity pathway analysis (IPA) software which identified several known hypertension pathways related to microarray data of SHR. Supplementary Figure S1 show changed genes that were identified in microarray by IPA. A schematic diagram in Supplementary Figure S3A and S3B summarized the experimental design and the data flow of IPA. The microarray data analyzed by IPA shows that MB gene is the most changed and has a relationship with hypertension including renal injury (Fig. 3A-B, Fig. 4 , and Supplementary Figure S1 ). Among the list of genes found in IPA in accord with microarray results, Mb protein located in the cytoplasm is tagged as a biomarker and diagnostic gene for kidney injury (Supplementary Table S5 ). The Mb protein, by upstream regulators through their specific molecule has both the direct and indirect activation including direct and indirect inhibition in the IPA predicted relationship which is channeled towards kidney injury and protection respectively. A partial list of upstream regulators prediction of IPA is shown in Supplementary Table S3 . Interestingly, IPA toxicity analysis shows up to four abnormal conditions representing kidney damage/toxicity in the top five with threshold >2 (details in Fig. 3B and Supplementary Table S2) .
Interestingly, further validation for the reliability of Mb gene from SHR (control) using Western blot showed high signal on Mb band compared to normotensive WKY rats ( Fig. 5A  and B) . However, DHI treatment significantly decreased the renal Mb in SHR compared to the control. Similarly, positive control (Losartan) also exerted the same effect as DHI. In addition, several novel regulators that may play key roles in the onset and progression of DHI renal protection (Fig. 3A, Supplementary Table S4 ) were identified.
Recently published evidence confirms the toxic effects of Mb on the kidney presented as over-expression [12, 39, 40] . Therefore, our results seem to support that renal protection of DHI in SHR is preferentially triggered by Mb gene down-regulation.
However, the exact relationship between KIM-1 expression and hypertension remains undefined. Although the down-regulation of KIM-1 by DHI raised an intriguing possibility of searching for other drugs that target KIM-1 in treating the hypertension-related renal injury. One major limitation of our study is that whether the renal injury markers such as KIM-1 and Mb that were reversed by DHI were the consequences of systemic BP lowing or acting directly on the kidney is unexplored. Therefore, further studies are needed to distinguish the direct vs. indirect impact of DHI on renal protection in hypertension. The majority of differentially expressed genes by DHI treatment in our microarray study remain unexplored. Future studies using a combined approach of bioinformatics and molecular biology may further elucidate DHI's molecular targets and therapeutic potentials in hypertensive kidney injury prevention.
Conclusion
A previous study showed that KIM-1 was up-regulated in SHR during kidney injury [41] suggesting a possible link with blood pressure elevation and renal injury. Our renal-specific microarray analysis in this study suggested that DHI might play such a role. To the best of our knowledge, there is no drug treatment that alleviates hypertension associated renal injury by down-regulation of KIM-1. Since we have only investigated DHI in its multi-components nature, another required research direction is to define the precise active components that are responsible for the renal benefits of a complex herbal medicine.
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